TY - JOUR
T1 - Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens
T2 - open issues
AU - Cornaglia, Giuseppe
AU - Akova, Murat
AU - Amicosante, Gianfranco
AU - Cantón, Rafael
AU - Cauda, Roberto
AU - Docquier, Jean Denis
AU - Edelstein, Mikhail
AU - Frère, Jean Marie
AU - Fuzi, Miklós
AU - Galleni, Moreno
AU - Giamarellou, Helen
AU - Gniadkowski, Marek
AU - Koncan, Raffaella
AU - Libisch, Balázs
AU - Luzzaro, Francesco
AU - Miriagou, Vivi
AU - Navarro, Ferran
AU - Nordmann, Patrice
AU - Pagani, Laura
AU - Peixe, Luisa
AU - Poirel, Laurent
AU - Souli, Maria
AU - Tacconelli, Evelina
AU - Vatopoulos, Alkiviadis
AU - Rossolini, Gian Maria
PY - 2007/4
Y1 - 2007/4
N2 - The rapid spread of acquired metallo-β-lactamases (MBLs) among major Gram-negative pathogens is a matter of particular concern worldwide and primarily in Europe, one of first continents where the emergence of acquired MBLs has been reported and possibly the geographical area where the increasing diversity of these enzymes and the number of bacterial species affected are most impressive. This spread has not been paralleled by accuracy/standardisation of detection methods, completeness of epidemiological knowledge or a clear understanding of what MBL production entails in terms of clinical impact, hospital infection control and antimicrobial chemotherapy. A number of European experts in the field met to review the current knowledge on this phenomenon, to point out open issues and to reinforce and relate to one another the existing activities set forth by research institutes, scientific societies and European Union-driven networks.
AB - The rapid spread of acquired metallo-β-lactamases (MBLs) among major Gram-negative pathogens is a matter of particular concern worldwide and primarily in Europe, one of first continents where the emergence of acquired MBLs has been reported and possibly the geographical area where the increasing diversity of these enzymes and the number of bacterial species affected are most impressive. This spread has not been paralleled by accuracy/standardisation of detection methods, completeness of epidemiological knowledge or a clear understanding of what MBL production entails in terms of clinical impact, hospital infection control and antimicrobial chemotherapy. A number of European experts in the field met to review the current knowledge on this phenomenon, to point out open issues and to reinforce and relate to one another the existing activities set forth by research institutes, scientific societies and European Union-driven networks.
KW - Antimicrobial resistance
KW - Metallo-β-lactamases
UR - http://www.scopus.com/inward/record.url?scp=33847377956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847377956&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2006.10.008
DO - 10.1016/j.ijantimicag.2006.10.008
M3 - Article
C2 - 17223319
AN - SCOPUS:33847377956
VL - 29
SP - 380
EP - 388
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
SN - 0924-8579
IS - 4
ER -